Search clinical trials for: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)

Total 108 results

Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
Abbott Medical Devices

Terminated

ABSORB PHYSIOLOGY Clinical Investigation

Coronary Artery Disease

Netherlands, Australia, Singapore, China
Medtronic Vascular
Medtronic Bakken Research Center

Completed

Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent (RESOLUTE-AC)

Coronary Artery Disease

Switzerland
Abbott Medical Devices

Completed

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study (XV CHINA SAS)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Stent Thrombosis | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis | Angioplasty

United States
Odense University Hospital

Completed

The SOURT OUT IV TRIAL (SORT OUT IV)

Ischemic Heart Disease | Percutaneous Coronary Intervention | Coronary Atherosclerosis

Denmark
European Hospital

Completed

Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease (RENAL-DES)

Chronic Kidney Disease | Multivessel Coronary Artery Disease

Italy
Deutsches Herzzentrum Muenchen

Unknown

Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents (ISAR-TEST6)

Coronary Heart Disease

Germany
Foundation of Cardiovascular Research and Education...

Completed

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente (TWENTE)

Coronary Artery Disease | Angina Pectoris | Unstable Angina Pectoris | Coronary Stenosis | Coronary Restenosis

Netherlands
Abbott Medical Devices

Completed

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

Coronary Artery Disease

United States
Abbott Medical Devices

Completed

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Myocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery Restenosis

United States
Abbott Medical Devices

Completed

SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System (SPIRIT II)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Netherlands, Spain, Denmark, Germany, France, Austria, Belgium, India, Italy, New Zealand, Poland, South Africa, Switzerland
Flanders Medical Research Program

Completed

Drug Eluting Stents In The Critically Ischemic Lower Leg (DESTINY)

Peripheral Vascular Disease | Critical Limb Ischemia

Belgium, France, Germany
Abbott Medical Devices

Completed

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Occlusion | Coronary Restenosis | Vascular Disease | Coronary Artery Stenosis | Thrombosis (Stent Thrombosis)

China
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1) (XVU-Phase 1)

Coronary Artery Disease

United States
Deutsches Herzzentrum Muenchen

Completed

Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography (TEST-6-OCT)

Coronary Heart Disease

Germany
Abbott Medical Devices

Terminated

SPIRIT Small Vessel Registry (SPIRIT SV)

Myocardial Ischemia | Coronary Artery Disease | Atherosclerosis

United States
Abbott Medical Devices

Completed

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS)

Myocardial Infarction | Coronary Artery Disease | Cardiovascular Disease | Coronary Heart Disease | Stent Thrombosis | Coronary Restenosis | Vascular Disease | Angioplasty

United States
North Texas Veterans Healthcare System

Completed

Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions (SOS-Xience V)

Coronary Artery Bypass | Atherosclerosis

United States
Cordis Corporation

Terminated

An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II) (NEVO II)

Atherosclerotic Coronary Artery Disease

Spain, Switzerland, Netherlands
Spanish Society of Cardiology

Unknown

Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple Versus Complex Techniques

Coronary Artery Disease

Spain
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) (XVU-LTF)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis

United States
Abbott Medical Devices

Completed

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA)

Coronary Artery Disease | Coronary Disease | Coronary Stenosis | Coronary Artery Stenosis

United States
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Active, not recruiting

Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease | Antineoplastic Agents

China
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus (ESSENCE-DM)

Coronary Artery Disease

Korea, Republic of
Lepu Medical Technology (Beijing) Co., Ltd.

Unknown

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Coronary Artery Disease

China
San Giuseppe Moscati Hospital

Completed

Everolimus Stent in Patients With Coronary Artery Disease (CAD) (RACES)

Coronary Artery Disease | Coronary Atherosclerosis

Italy
Deutsches Herzzentrum Muenchen

Unknown

Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography (ZES/EES-OCT)

Coronary Heart Disease

Germany
Sahajanand Medical Technologies Pvt. Ltd.
Cardialysis BV

Terminated

SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

Coronary Artery Disease

India, Brazil, Saudi Arabia
Universitaire Ziekenhuizen KU Leuven
Biosensors International

Unknown

COmplex BifuRcation Lesions: a Comparison Between the AXXESS Device and Culotte Stenting: an Optical Coherence Tomography (OCT) Study (COBRA)

True Coronary Bifurcation Lesions

Belgium
Odense University Hospital

Completed

Comparison of Coronary Xience V and the Cypher Select+ Stents in Diabetic Patients (DIABEDES IV)

Diabetes Mellitus

Denmark
Sino Medical Sciences Technology Inc.

Completed

A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT

Coronary Artery Disease | Stable Angina Pectoris | Unstable Angina Pectoris

China
Brighton and Sussex University Hospitals NHS Trust
Abbott Medical Devices

Completed

Xience or Vision Stent Management of Angina in the Elderly (XIMA)

Coronary Artery Disease

United Kingdom
Universitaire Ziekenhuizen KU Leuven

Completed

STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study (STACCATO)

Coronary Artery Disease

Belgium
Cardiovascular Research Foundation, New York
Dickson Advanced Analytics Group

Completed

Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES)

Coronary Artery Disease

United States
Abbott Medical Devices

Completed

SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Netherlands, Thailand, Israel, Spain, Italy, United Kingdom, Malaysia, Austria, France, Germany, Poland
Yonsei University
Gangwon Cardiovascular Health Research Institute

Terminated

BES, EES, and ZES-R in Real World Practice (CHOICE)

Coronary Artery Disease

Korea, Republic of
Hospital Universitario Infanta Cristina

Unknown

The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients (TITANIC-XV)

Diabetes Mellitus | Percutaneous Coronary Intervention

Spain, Finland
Yonsei University
Medtronic

Completed

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction (EVERZOTA)

Myocardial Infarction

Korea, Republic of
Abbott Medical Devices

Completed

EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease (EXecutive)

Coronary Artery Disease | Coronary Disease | Coronary Artery Stenosis | Coronary Artery Restenosis

Italy
Spanish Society of Cardiology

Unknown

Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR)

Coronary Artery Disease | Diabetes Mellitus

Spain
Yonsei University

Unknown

Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation (ANCHOR)

Coronary Artery Disease

Korea, Republic of
Abbott Medical Devices

Completed

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Stent Thrombosis | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis | Angina

Japan
Universitaire Ziekenhuizen KU Leuven

Withdrawn

COmplex BifuRcation Lesions: A Comparison Between the AXXESS Device and Culotte Stenting: An Optical Coherence Tomography (OCT) Study (COBRA)

Coronary Artery Stenosis

Belgium
Deutsches Herzzentrum Muenchen

Unknown

Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World (ZEPPELIN)

Coronary Artery Disease

Germany
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent (DES-ISR)

In-stent Restenosis

Korea, Republic of
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III) (LONG-DES-III)

Coronary Artery Disease

Korea, Republic of
Deutsches Herzzentrum Muenchen
Technical University of Munich

Completed

Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease (LEFT-MAIN-2)

Coronary Disease

Germany, Italy
Concept Medical Inc.

Active, not recruiting

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global (ABILITY)

Coronary Artery Disease | Diabetes | Acute Coronary Syndrome

Switzerland, Australia, Korea, Republic of, France, Belgium, Netherlands, United Kingdom, India, Austria, Bangladesh, Brazil, Czechia, Germany, Ireland, Italy, Malaysia, Mexico, Poland, Singapore, Sweden, Taiwan
Shanghai MicroPort Medical (Group) Co., Ltd.

Active, not recruiting

Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

Percutaneous Coronary Intervention | Drug-Eluting Stents | Tomography, Optical Coherence

China

Search clinical trials for: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations